Deepbridge Capital

Spotlight Pathology focuses on creating decision support tools that leverage artificial intelligence to enhance the diagnosis of blood cancers. The company's medical diagnostic platform integrates bioinformatics and genomics, utilizing AI to analyze digital histopathology and multiplex immunofluorescence images. This innovative approach aids healthcare professionals in detecting and diagnosing blood cancers at an early stage, ultimately improving patient outcomes. By combining advanced technology with medical expertise, Spotlight Pathology aims to transform the diagnostic landscape for blood-related malignancies.

HeadBox is a UK-based online marketplace that connects corporate and SME event planners directly with owners of unique, inspiring, and off-site meeting spaces. Its platform enables users to search, book, and pay for spaces online, streamlining the event planning process. HeadBox caters to a wide range of events, including workshops, meetings, product launches, and corporate parties, helping both guests and hosts unlock revenue and reduce hassle. Founded in 2015, the company is headquartered in Reading, United Kingdom.

AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.

Microplate Dx is a developer of diagnostic technology focused on reducing fatalities from drug-resistant infections. As an award-winning spinout from the University of Strathclyde in Glasgow, the company aims to address the global health challenge of antimicrobial resistance. Microplate Dx's innovative solutions utilize highly sensitive biosensor electrodes, combined with miniaturized hydrogel deposits containing antibiotics specific to the infection being detected. Their medical diagnostic device provides a low-cost and accurate point-of-care alternative, enabling rapid antibiotic prescribing in under one hour. This approach enhances antibiotic stewardship and strives to manage the spread of antimicrobial resistance effectively.

Thalia Design Automation Ltd. is a semiconductor electronic design automation (EDA) company based in Bath, United Kingdom, with an engineering center in Hyderabad, India. Established in 2011, the company specializes in software solutions for the design of analog and mixed-signal integrated circuits. Thalia offers AMALIA, an analog circuit optimizer toolset that employs advanced methodologies and algorithms for circuit solutions, and EMERA, a toolset focused on the design and optimization of power devices using finite element decomposition. Additionally, Thalia provides analog circuit porting services and offers its solutions as Software as a Service (SaaS), allowing customers to access the tools either onsite or via the cloud. The company also engages in custom power device development as an intellectual property service, facilitating the reuse and optimization of existing designs for new technologies and applications.

IbisVision Limited specializes in developing a visual field test software application aimed at the early detection of glaucoma, a leading cause of blindness worldwide. The company's primary product, Ring of Sight (ROS), is a cloud-based solution that enables healthcare professionals to conduct eye tests efficiently. Utilizing patented technology, ROS integrates various eye tests into a single device, offering both Full Threshold and Suprathreshold tests. It is designed for remote and in-practice use, allowing optometrists to deliver high-quality eye care while optimizing their investment. The application operates within a Windows environment and ensures that all patient data is securely stored on encrypted servers to uphold privacy and security. Founded in 2013 and headquartered in Livingston, United Kingdom, IbisVision is committed to advancing eye care through innovative technology.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

Circada's unique lighting controls improve health and well-being. This consists of an adapter that connects to existing tuneable white LED drivers and is simple to retrofit without the need for complex commissioning, with a standard light switch serving as its interface. We can provide additional configuration prior to installation if necessary for a specific project in order to match the lighting specification, once again providing advanced circadian lighting that is plug-and-play and commission free.

Touch Biometrix Ltd is a UK-based company that designs and develops innovative fingerprint authentication sensors for the consumer electronics sector. Established in 2017 and headquartered in Conwy, the company focuses on creating a versatile sensing and algorithm platform that allows for fingerprint sensors of various shapes and sizes. This technology is engineered for seamless integration into mobile devices and other smart objects, enhancing user-friendly identity authentication. By employing advanced sensor designs and algorithms, Touch Biometrix aims to provide a secure and convenient alternative to traditional password systems, enabling a range of products to deliver high-performance fingerprint authentication at competitive cost points.

FluoretiQ Limited is a medical device company based in Bristol, United Kingdom, that focuses on developing advanced technologies for the rapid identification of harmful bacteria. Founded in 2017, the company has created a diagnostic platform known as NANOPLEX, which utilizes proprietary nanomaterials and optical sensing technologies to detect bacterial pathogens in under 15 minutes. This innovative approach combines receptor-mediated sensing with quantum-enhanced optics, facilitating early diagnosis and enabling healthcare professionals to prescribe effective antibiotic treatments more efficiently. FluoretiQ's user-friendly products support accurate same-day diagnoses, ultimately improving patient outcomes by ensuring timely and appropriate antibiotic selection.

Pathfinder Medical is focused on creating a novel electronic guidance system that facilitates minimally invasive connections between blood vessels. This innovative catheter-based technology is designed specifically for treating kidney failure, allowing for vascular access creation that can be performed outside of traditional operating rooms. The system aims to improve the reliability of hemodialysis access for patients, addressing a significant market opportunity valued at £1.6 billion annually. By reducing the likelihood of failure, Pathfinder Medical’s solution enhances treatment options for patients requiring dialysis, showcasing its potential impact in the healthcare sector.

Aegiq Ltd. is a company based in Sheffield, United Kingdom, specializing in semiconductor-based quantum photonic chips. Established in 2019, it focuses on developing a universal quantum computing platform that integrates photonic quantum computing and networking technologies. Aegiq's solutions cater to a variety of industries, including defense, aerospace, cybersecurity, and artificial intelligence, addressing complex computational challenges with an emphasis on speed, compactness, and modularity. The company's innovative hybrid integrated photonics approach aims to facilitate large-scale quantum computing with the capacity for multi-million qubit operations, ultimately contributing to advancements in quantum cybersecurity and networking.

Glucose Republic is a developer of software focused on enhancing metabolic health through personalized nutrition solutions. The company offers a specialized application that enables users to measure and predict their metabolic responses based on their dietary intake and physical activity. By leveraging biology-influenced technology, Glucose Republic aims to provide individuals with tools to better understand their metabolism, ultimately helping them to eat and live healthier.

Glyconics Ltd. is a diagnostics company based in Cambridge, United Kingdom, specializing in the development of portable infrared spectroscopy devices for the diagnosis and monitoring of chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Established in 2013, the company has created a hand-held device that utilizes Fourier transform infrared spectroscopy (FTIR) to analyze sputum samples for specific biomarkers associated with COPD. This innovative technology allows patients to perform diagnoses and monitor their health from home, facilitating early detection and management of respiratory diseases. By identifying particular spectral signatures in the samples, the device supports healthcare professionals in assessing and understanding patients' conditions more effectively.

SmallSpark is a Welsh aerospace company based in Cardiff Bay, focused on developing hybrid engine launch vehicle technology. The company aims to significantly reduce the cost of access to space, making it feasible for a wide range of clients to send payloads into orbit or on sounding rockets. By offering low-cost space vehicles, SmallSpark enables customers to utilize advanced hybrid rocket motor technology, thereby democratizing access to space and fostering broader commercial opportunities in the aerospace sector.

HeadBox is a UK-based online marketplace that connects corporate and SME event planners directly with owners of unique, inspiring, and off-site meeting spaces. Its platform enables users to search, book, and pay for spaces online, streamlining the event planning process. HeadBox caters to a wide range of events, including workshops, meetings, product launches, and corporate parties, helping both guests and hosts unlock revenue and reduce hassle. Founded in 2015, the company is headquartered in Reading, United Kingdom.

Ferryx is focused on addressing the challenges posed by gut inflammation, particularly conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), which collectively affect millions globally. The company specializes in the development of live biotherapeutics, creating safe and effective bacterial products aimed at preventing and treating gastrointestinal inflammation. By providing natural alternatives to conventional medications, Ferryx seeks to offer solutions that minimize negative side effects and enhance the well-being of both humans and animals suffering from these debilitating conditions.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

Viscgo Limited is a company based in Warrington, United Kingdom, founded in 2015. It specializes in designing, developing, and delivering innovative devices and technology aimed at improving the management of dysphagia, a condition that affects individuals with swallowing disorders. Viscgo's product line includes drink thickness testers that enable accurate measurement of the viscosity of various liquids and textured-modified foods. This technology aids patients, caregivers, and clinicians by ensuring that fluids are properly mixed to provide a smooth consistency, thereby enhancing the safety and quality of care in settings such as hospitals, care homes, schools, and nurseries.

Filisia Interfaces Ltd. specializes in developing multimedia and multisensory devices aimed at enhancing training and rehabilitation for individuals with special education and rehabilitation needs. Founded in 2014 and based in London, the company offers Monoma, a training system designed for people with learning and physical disabilities. Filisia’s solutions leverage creative technology, integrating music and games to engage users in physical, cognitive, and communication skill development. The company's software features gamified rehabilitation exercises tailored to various conditions, with multiple difficulty levels to assess and improve user capabilities. Additionally, it provides valuable data analytics to track progress in physical and cognitive skills, addressing the challenges of traditional rehabilitation methods, which can be costly and monotonous. By focusing on innovative, engaging training solutions, Filisia aims to optimize therapy outcomes and reduce care costs for the estimated 150 million individuals worldwide with special education and rehabilitation needs.

VoxSmart Limited is a telecommunications software provider based in London, specializing in solutions for financial services companies both in the United Kingdom and internationally. Founded in 2006, the company offers VSMART, a comprehensive software solution designed to capture, record, store, transcribe, and analyze employee communications, including mobile calls, messages, and voicemails across various devices and networks. VoxSmart's technology enables firms to manage business risk and comply with regulatory requirements by transforming captured data into actionable insights regarding employee conduct and operational efficiency. With a team of experts in finance, regulation, and business analytics, VoxSmart aims to enhance clients' decision-making processes and improve their overall business operations. The company has also formed a strategic alliance with Eventus Systems, Inc. to further strengthen its offerings.

We help Startups with their digital products.

Carocell Bio is a biotechnology company focused on developing innovative medicines to address serious inflammatory disorders. The company aims to provide safer and more effective treatment options for conditions such as atopic dermatitis, inflammatory bowel disease, and burn-related injuries. Its platform utilizes human biopsy samples to enhance the management of these inflammatory conditions, allowing medical professionals to prevent scarring following surgeries or burns. With a goal of becoming revenue-generating within five years, Carocell Bio plans to drive its lead project towards a potential exit through out-licensing or trade sale, thereby advancing its commitment to improving patient outcomes in inflammatory disorders.

Circada's unique lighting controls improve health and well-being. This consists of an adapter that connects to existing tuneable white LED drivers and is simple to retrofit without the need for complex commissioning, with a standard light switch serving as its interface. We can provide additional configuration prior to installation if necessary for a specific project in order to match the lighting specification, once again providing advanced circadian lighting that is plug-and-play and commission free.

NanOptima is focused on improving the treatment of retinal diseases through innovative ophthalmic drug delivery technology. The company is developing controlled-release drug depots that aim to reduce the frequency of intraocular injections to twice a year, enhancing patient compliance and comfort. By maintaining consistent intraocular medication concentrations, NanOptima addresses the limitations of traditional injection methods. Their approach involves utilizing approved drugs to provide effective treatment for conditions such as wet age-related macular degeneration. Additionally, the technology is designed to facilitate the early detection of eye diseases and disorders, ultimately aiming to improve patient outcomes and reduce the risk of incomplete treatment.

LogChain is a digital platform focused on transforming supply chain management to enhance efficiency, security, and compliance. By utilizing distributed ledger technology, LogChain captures data and documentation at every stage of the trade process, particularly benefiting chemical manufacturers and shippers. This approach allows clients to deliver shipments with reduced costs, time, and risk. The platform streamlines workflows, including customs clearance and logistics management, making it suitable for businesses of all sizes, from micro-businesses to multinationals. LogChain's commitment to transparency and security, along with its seamless integration into existing systems, positions it as a valuable partner in optimizing supply chains and improving overall operational performance.

SmallSpark is a Welsh aerospace company based in Cardiff Bay, focused on developing hybrid engine launch vehicle technology. The company aims to significantly reduce the cost of access to space, making it feasible for a wide range of clients to send payloads into orbit or on sounding rockets. By offering low-cost space vehicles, SmallSpark enables customers to utilize advanced hybrid rocket motor technology, thereby democratizing access to space and fostering broader commercial opportunities in the aerospace sector.

Circada's unique lighting controls improve health and well-being. This consists of an adapter that connects to existing tuneable white LED drivers and is simple to retrofit without the need for complex commissioning, with a standard light switch serving as its interface. We can provide additional configuration prior to installation if necessary for a specific project in order to match the lighting specification, once again providing advanced circadian lighting that is plug-and-play and commission free.

Liverpool ChiroChem Limited, established in 2014, is a UK-based company specializing in the production of chiral small molecules for biotech and pharmaceutical research and development. It offers a range of products, including 3D heterocyclic and carbocyclic API and intermediates, custom synthesis services, building blocks for DNA-encoded library synthesis, and fragment libraries. These products serve as essential building blocks, fragments, and screening compounds, facilitating small molecule drug discovery. The company's expertise lies in asymmetric hydrogenation and Pd-coupling technologies, enabling efficient access to novel chiral building blocks and a wide range of chiral amines with excellent enantiomeric purity. Liverpool ChiroChem's initial focus is on the production and supply of chiral piperidines and other sp3-rich nitrogen heterocycles, which are crucial in drug discovery due to their favorable pharmacokinetic properties. The company collaborates with customers to optimize synthetic routes, providing tailored solutions to meet specific research needs.

Blossom Genetics produces proprietary medicinal cannabis genetics and products. Our mission is to advance medicinal cannabis through scientific research to develop best in class products for our customers.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Ostara Biomedical Ltd. is a biotechnology company focused on enhancing artificial reproduction technologies for various mammalian species. Based in Liverpool, United Kingdom, the company has developed a novel vaginal pessary system designed to induce pseudopregnancy in female mice, facilitating embryo transfers. Ostara's ProgenySys™ product suite aims to improve the success rates of artificial reproduction in both domestic livestock and laboratory rodents, while also addressing ethical concerns by minimizing the number of animals required in breeding programs. Founded in 2012, Ostara serves customers both in the UK and internationally, contributing to advancements in reproductive technologies that support individuals and healthcare providers on the fertility journey.

Thalia Design Automation Ltd. is a semiconductor electronic design automation (EDA) company based in Bath, United Kingdom, with an engineering center in Hyderabad, India. Established in 2011, the company specializes in software solutions for the design of analog and mixed-signal integrated circuits. Thalia offers AMALIA, an analog circuit optimizer toolset that employs advanced methodologies and algorithms for circuit solutions, and EMERA, a toolset focused on the design and optimization of power devices using finite element decomposition. Additionally, Thalia provides analog circuit porting services and offers its solutions as Software as a Service (SaaS), allowing customers to access the tools either onsite or via the cloud. The company also engages in custom power device development as an intellectual property service, facilitating the reuse and optimization of existing designs for new technologies and applications.

Pacla Medical is the creator of BackHug, an innovative robotic device designed to alleviate back pain and improve spinal flexibility. Utilizing patent-protected technology, BackHug employs 26 robotic fingers to deliver deep tissue pressure to the center of the back and shoulder blades, achieving an average pain reduction of 51%. The accompanying BackHug App personalizes treatment plans through an in-app consultation, allowing users to adjust strength and parameters in real-time. The device also monitors back relaxation levels and utilizes artificial intelligence to optimize treatment based on user data. With a growing customer base, users report significant savings on traditional treatments, averaging over $500 per month, and typically engage with the device 2-3 times a week. Employing approximately 16 staff across the UK and Vietnam, Pacla Medical aims to transform the lives of over 197 million individuals suffering from back pain and related conditions.

Filisia Interfaces Ltd. specializes in developing multimedia and multisensory devices aimed at enhancing training and rehabilitation for individuals with special education and rehabilitation needs. Founded in 2014 and based in London, the company offers Monoma, a training system designed for people with learning and physical disabilities. Filisia’s solutions leverage creative technology, integrating music and games to engage users in physical, cognitive, and communication skill development. The company's software features gamified rehabilitation exercises tailored to various conditions, with multiple difficulty levels to assess and improve user capabilities. Additionally, it provides valuable data analytics to track progress in physical and cognitive skills, addressing the challenges of traditional rehabilitation methods, which can be costly and monotonous. By focusing on innovative, engaging training solutions, Filisia aims to optimize therapy outcomes and reduce care costs for the estimated 150 million individuals worldwide with special education and rehabilitation needs.

Touch Biometrix Ltd is a UK-based company that designs and develops innovative fingerprint authentication sensors for the consumer electronics sector. Established in 2017 and headquartered in Conwy, the company focuses on creating a versatile sensing and algorithm platform that allows for fingerprint sensors of various shapes and sizes. This technology is engineered for seamless integration into mobile devices and other smart objects, enhancing user-friendly identity authentication. By employing advanced sensor designs and algorithms, Touch Biometrix aims to provide a secure and convenient alternative to traditional password systems, enabling a range of products to deliver high-performance fingerprint authentication at competitive cost points.

As featured on the BBC, TimeOut London, Evening Standard, and Conde Nast Traveler. TubeChat is the only free to download iPhone group messaging app that works on the London Underground where there is no cellular or wifi. TubeChat uses Bluetooth on your iPhone to make automatic incognito connections to people with the same app up to 200 meters away allowing you to chat and play underground. What can you do on TubeChat? LINK - UP: Make new friends. TubeChat facilitates real-life conversations and meetings in areas where other popular social networking or dating apps just don’t work. CHAT: Group chat safely completely ad-free with up to 10 other users nearby. We don’t reveal your identity unless you want to. Maintain your mystery by not updating your profile picture. PLAY: With TubeChat you will be able to play classic games such as I Spy. Have you got a favourite game you’d like to see in the app? Let us know and we’ll see what we can do.

Compono is a software company that specializes in intelligent hiring solutions aimed at enhancing recruitment processes. The company develops a platform that utilizes data, science, and technology to optimize the hiring, development, and engagement of employees. By employing a unique algorithm, Compono's software matches candidates to specific job requirements, actively comparing and contrasting their skills and qualifications. This approach allows recruiters to rank candidates according to their suitability for roles, ultimately facilitating better organizational design and improving workforce productivity. Through its innovative solutions, Compono strives to unlock the potential of both individuals and organizations in the hiring landscape.

Keia is an online platform that connects wellness service practitioners with consumers, offering a wide range of services including acupuncture, massage, physiotherapy, relationship counseling, and yoga. With coverage spanning 27 areas and continually expanding, Keia aims to make wellness services accessible and affordable for everyone. The company provides healthcare professionals with a comprehensive suite of cloud-based business management software, enabling them to efficiently manage and grow their practices. By leveraging technology, Keia facilitates easier access to wellness therapies and helps patients find qualified practitioners in their local communities.

JammToday is an online platform designed to assist users in comparing and reviewing various robo- and passive investment providers. By allowing users to input their investment objectives and preferences, JammToday generates a tailored list of suitable digital investment managers. This service addresses the significant advice gap in the UK, where millions lack access to traditional financial advice. The platform simplifies the investment process by providing direct links to the chosen providers' websites, enabling users to complete their investment journey seamlessly. JammToday effectively serves both novice savers and experienced investors, making it easier to navigate the diverse landscape of robo-investing options.

Mynurva is an online therapy platform based in the UK that focuses on transforming behavioral health services through technology. By offering counseling sessions via live video chats with expert therapists, Mynurva aims to make high-quality and reliable mental health services accessible to everyone. The platform is designed to ensure that users can receive care discreetly and securely, providing a convenient option for individuals seeking support for their mental well-being.

Chainvine Ltd, established in 2015 and headquartered in Ipswich, UK, specializes in developing bespoke blockchain-based platforms for identity, asset, and encryption management. Its distributed ledger technology (DLT) decentralizes data across a network of nodes, providing secure, permanent cloud storage for transactional data. Chainvine's key products include Intelligent Commodities, which integrates with IoT partners to track physical commodities and record supply chain data, and Intelligent Contracts, enabling businesses to manage digital contracts and store data changes. The company supports multiple blockchain technologies and offers enterprise-grade security, increasing businesses' financial margins and accountability.

Touch Biometrix Ltd is a UK-based company that designs and develops innovative fingerprint authentication sensors for the consumer electronics sector. Established in 2017 and headquartered in Conwy, the company focuses on creating a versatile sensing and algorithm platform that allows for fingerprint sensors of various shapes and sizes. This technology is engineered for seamless integration into mobile devices and other smart objects, enhancing user-friendly identity authentication. By employing advanced sensor designs and algorithms, Touch Biometrix aims to provide a secure and convenient alternative to traditional password systems, enabling a range of products to deliver high-performance fingerprint authentication at competitive cost points.

VTime is a virtual reality software company focused on redefining virtual engagement and communication through innovative applications and cloud-based solutions. Its flagship product, vTime, is a social VR app that allows users to connect and interact in immersive environments. Available for free since December 2015, vTime has attracted hundreds of thousands of users globally, establishing itself as a leader in the European technology sector. The platform facilitates meaningful connections by offering unique ways to engage with friends, family, and communities in virtual settings, enabling users to chat and share media while spending quality time together, regardless of their physical locations.

Liverpool ChiroChem Limited, established in 2014, is a UK-based company specializing in the production of chiral small molecules for biotech and pharmaceutical research and development. It offers a range of products, including 3D heterocyclic and carbocyclic API and intermediates, custom synthesis services, building blocks for DNA-encoded library synthesis, and fragment libraries. These products serve as essential building blocks, fragments, and screening compounds, facilitating small molecule drug discovery. The company's expertise lies in asymmetric hydrogenation and Pd-coupling technologies, enabling efficient access to novel chiral building blocks and a wide range of chiral amines with excellent enantiomeric purity. Liverpool ChiroChem's initial focus is on the production and supply of chiral piperidines and other sp3-rich nitrogen heterocycles, which are crucial in drug discovery due to their favorable pharmacokinetic properties. The company collaborates with customers to optimize synthetic routes, providing tailored solutions to meet specific research needs.

Renephra Ltd. is a medical device company based in Manchester, United Kingdom, established in 2009. It specializes in developing innovative Transdermal Fluid Removal (TFR) technology aimed at addressing fluid overload and chronic conditions such as oedema and lymphoedema. The company's devices utilize a micro-needle system combined with negative pressure therapy to facilitate minimally invasive fluid removal from the skin. This technology targets significant clinical needs within vascular and oncology patients, representing a large and underserved market estimated at £1 billion globally. Having achieved proof of concept in human trials, Renephra is currently seeking funding to advance its device development and feasibility studies.

Zilico Limited is a Manchester-based company focused on developing diagnostic devices aimed at improving cancer detection, particularly cervical cancer. Utilizing electrical impedance spectroscopy technology, Zilico's flagship product, ZedScan, operates alongside colposcopy to provide real-time, objective assessments of cervical epithelial tissue. This technology addresses the limitations of traditional diagnostic methods, which often involve subjective interpretations. Zilico is actively working on two applications: one targeting the referral market and another aimed at the screening market, both designed to enhance diagnostic accuracy and reduce the subjectivity associated with current practices. Since its founding in 2006, Zilico has aimed to deliver significant health economic benefits and improve cancer screening programs. The company was previously known as Aperio Diagnostics Limited before rebranding in 2008.

Keia is an online platform that connects wellness service practitioners with consumers, offering a wide range of services including acupuncture, massage, physiotherapy, relationship counseling, and yoga. With coverage spanning 27 areas and continually expanding, Keia aims to make wellness services accessible and affordable for everyone. The company provides healthcare professionals with a comprehensive suite of cloud-based business management software, enabling them to efficiently manage and grow their practices. By leveraging technology, Keia facilitates easier access to wellness therapies and helps patients find qualified practitioners in their local communities.

Hurricane Modular Commerce Limited, founded in 2016 and based in Saint Albans, United Kingdom, specializes in providing a fully compliant landed cost engine. The company leverages over 100 years of combined experience in logistics, transport, and information technology to offer tailored solutions for businesses. Hurricane Modular Commerce focuses on delivering a flexible pricing structure that enables clients to accurately budget for tax and import duty calculations, ensuring compliance and efficiency in their operations.

Cell Lane Ltd has been established to develop a cell isolation and separation platform technology, based on intellectual property assigned from the University of Leeds. This new technology seeks to assist in the future treatment of chronic diseases such as cancer and AIDS, and is intended to enable new fields of research in research activities such stem cell research. The Company’s proposed technology can be used to rapidly separate cells whilst preserving their functionality and overall viability. Cell Lane is in the process of developing its technology to a point where it has a Minimum Viable Product (‘MVP’), the MVP (i.e. the new platform) will then be developed and taken forwards to be commercialised by the Company.

Pacla Medical is the creator of BackHug, an innovative robotic device designed to alleviate back pain and improve spinal flexibility. Utilizing patent-protected technology, BackHug employs 26 robotic fingers to deliver deep tissue pressure to the center of the back and shoulder blades, achieving an average pain reduction of 51%. The accompanying BackHug App personalizes treatment plans through an in-app consultation, allowing users to adjust strength and parameters in real-time. The device also monitors back relaxation levels and utilizes artificial intelligence to optimize treatment based on user data. With a growing customer base, users report significant savings on traditional treatments, averaging over $500 per month, and typically engage with the device 2-3 times a week. Employing approximately 16 staff across the UK and Vietnam, Pacla Medical aims to transform the lives of over 197 million individuals suffering from back pain and related conditions.

Sky Medical Technology Limited develops innovative neuromuscular electro-stimulation medical devices aimed at enhancing vascular health. Their flagship products include the geko device, which stimulates the common peroneal nerve to activate muscle pumps and improve blood flow, and the firefly device, designed for athletes to enhance lower limb circulation for quicker recovery. The company's OnPulse™ therapy represents a significant advancement in bioelectronic medicine, offering clinically proven solutions for various acute and chronic circulatory conditions, including the prevention of blood clots, treatment of swelling post-surgery, and management of non-healing wounds. These devices are utilized by healthcare professionals, including surgeons, nurses, physiotherapists, and podiatrists, across NHS and private hospitals, as well as in clinical studies. Sky Medical Technology distributes its products globally, reaching markets in Asia, Europe, the Middle East, and North America. Founded in 2006 and based in High Wycombe, United Kingdom, the company addresses the needs of over forty million individuals facing vascular-related health challenges.

Pathfinder Medical is focused on creating a novel electronic guidance system that facilitates minimally invasive connections between blood vessels. This innovative catheter-based technology is designed specifically for treating kidney failure, allowing for vascular access creation that can be performed outside of traditional operating rooms. The system aims to improve the reliability of hemodialysis access for patients, addressing a significant market opportunity valued at £1.6 billion annually. By reducing the likelihood of failure, Pathfinder Medical’s solution enhances treatment options for patients requiring dialysis, showcasing its potential impact in the healthcare sector.

Tookie Limited, founded in 2015 and headquartered in Liverpool, United Kingdom, specializes in developing and selling innovative medical vests specifically designed for children undergoing chemotherapy. The Tookie Vest for Oncology secures central venous catheters (CVCs), which are used for long-term medical treatments, thereby addressing a critical need for enhanced safety and comfort. Traditional methods of securing CVCs often lead to discomfort and anxiety for both patients and their parents, as lines may be left loose or inadequately taped. Tookie's vests aim to alleviate these issues by providing a secure fit that minimizes the risk of inadvertent catheter fallout and reduces the likelihood of infections, ultimately improving the overall well-being and quality of life for young patients.

DynamX Medical specializes in developing an innovative precancer screening system designed for rapid tissue biopsy analysis. This system is user-friendly and can be operated at the point of care by nurses, enhancing accessibility in clinical settings. The company's medical software aims to streamline the disease diagnosis process by increasing the speed and reliability of detection. This technology not only improves diagnostic efficiency but also helps healthcare institutions alleviate the strain on their resources. Through its advancements, DynamX Medical seeks to make significant contributions to early disease detection and patient care.

Pacla Medical is the creator of BackHug, an innovative robotic device designed to alleviate back pain and improve spinal flexibility. Utilizing patent-protected technology, BackHug employs 26 robotic fingers to deliver deep tissue pressure to the center of the back and shoulder blades, achieving an average pain reduction of 51%. The accompanying BackHug App personalizes treatment plans through an in-app consultation, allowing users to adjust strength and parameters in real-time. The device also monitors back relaxation levels and utilizes artificial intelligence to optimize treatment based on user data. With a growing customer base, users report significant savings on traditional treatments, averaging over $500 per month, and typically engage with the device 2-3 times a week. Employing approximately 16 staff across the UK and Vietnam, Pacla Medical aims to transform the lives of over 197 million individuals suffering from back pain and related conditions.

T-EDTA Limited was established to develop anti-biofilm technologies and infection control products. Anti-biofilm is used in advanced wound care products using the anti-biofilm agents tri sodium/tetra sodium EDTA (‘t-EDTA’). A biofilm is a group of microorganisms in which cells stick to each other and often adhere to a surface, such as wound. As such, they represent a major risk of woundsite infection. EDTA is a chemical which can inhibit the development of such biofilms. Biofilms are a major problem for human infections and medical device related infections due to their becoming resistant to antibiotics, with the result being wounds that are slow to heal, or not healing/remaining open. The patented tri and tetrasodium EDTA (‘T-EDTA’) can be used to prevent and control infection in three specific areas; advanced wound care, catheters and consumer wellness (Skin/foot fungal infections).

Levitex Foams Ltd specializes in the development and manufacturing of therapeutic mattresses designed to improve body alignment and posture, particularly for individuals who are bed-bound. Recognizing the significant risks associated with poor posture, such as pressure sores and sleep deprivation, the company has created a postural management sleep system, classified as a class 1 medical device. This innovative product is particularly beneficial for patients suffering from complex neurological conditions, including Multiple Sclerosis, Cerebral Palsy, Motor Neurone Disease, and those recovering from stroke or hypoxic brain injury. Levitex Foams aims to enhance patient comfort and health outcomes by providing a range of soft yet supportive pillows, toppers, and mattresses. The company is also a registered supplier to the National Health Service (NHS), reflecting its commitment to quality and efficacy in the healthcare market.

Keia is an online platform that connects wellness service practitioners with consumers, offering a wide range of services including acupuncture, massage, physiotherapy, relationship counseling, and yoga. With coverage spanning 27 areas and continually expanding, Keia aims to make wellness services accessible and affordable for everyone. The company provides healthcare professionals with a comprehensive suite of cloud-based business management software, enabling them to efficiently manage and grow their practices. By leveraging technology, Keia facilitates easier access to wellness therapies and helps patients find qualified practitioners in their local communities.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

SurveyMe is a mobile application that facilitates real-time customer feedback, known as 'Point of Experience' feedback. It offers a user-friendly platform for businesses to gather immediate insights, enabling them to make informed decisions and drive growth. The company incentivizes users to provide feedback by offering rewards and coupons, making the process engaging and rewarding. SurveyMe's unique value proposition lies in its speed and flexibility, providing businesses with instant, easy-to-understand management information.

VoxSmart Limited is a telecommunications software provider based in London, specializing in solutions for financial services companies both in the United Kingdom and internationally. Founded in 2006, the company offers VSMART, a comprehensive software solution designed to capture, record, store, transcribe, and analyze employee communications, including mobile calls, messages, and voicemails across various devices and networks. VoxSmart's technology enables firms to manage business risk and comply with regulatory requirements by transforming captured data into actionable insights regarding employee conduct and operational efficiency. With a team of experts in finance, regulation, and business analytics, VoxSmart aims to enhance clients' decision-making processes and improve their overall business operations. The company has also formed a strategic alliance with Eventus Systems, Inc. to further strengthen its offerings.

EligoChem Ltd specializes in the design and development of amphiphilic compound libraries aimed at enhancing drug discovery processes. Founded in 2012 and located in Sandwich, United Kingdom, the company offers a range of services, including the provision of drug-like compounds for screening and support in medicinal and computational chemistry for lead optimization. EligoChem has developed proprietary technology that enables the creation of highly water-soluble drugs, which are better absorbed by the human body. This technology is particularly advantageous for antibiotic drug discovery, as it addresses the challenge of sourcing compounds with desirable solubility characteristics. By focusing on the unique properties of amphiphilic compounds, EligoChem aims to improve the efficacy of drug development and provide safer drugs by design.

RealSpace is a cloud-based software empowering real estate professionals to effectively manage all aspects of running their business online. Real Space Limited has developed a novel, wide field-of-view multi-purpose synoptic virtual reality viewer called ‘SingleReality’, to exploit what the founders perceive as a gap in the growing VR market for a completely new headset design that offers a best-in-class user experience and is also significantly cheaper than other current available market offerings. The Company’s strategy is to offer a superior VR experience by delivering identical images to each eye from a single 2D, high resolution image. This synoptic approach is a novel addition to the VR Head-Mounted Display device market.

Viscgo Limited is a company based in Warrington, United Kingdom, founded in 2015. It specializes in designing, developing, and delivering innovative devices and technology aimed at improving the management of dysphagia, a condition that affects individuals with swallowing disorders. Viscgo's product line includes drink thickness testers that enable accurate measurement of the viscosity of various liquids and textured-modified foods. This technology aids patients, caregivers, and clinicians by ensuring that fluids are properly mixed to provide a smooth consistency, thereby enhancing the safety and quality of care in settings such as hospitals, care homes, schools, and nurseries.

Parkure Ltd is a drug discovery company focused on researching and developing treatments for Parkinson's disease. Founded in 2014 and based in Edinburgh, United Kingdom, Parkure employs an innovative in-vivo drug discovery platform that utilizes fruit flies for drug screening and repurposing. This approach aims to mitigate risks in the drug development process by testing drugs in living organisms rather than in vitro methods. By concentrating on the degeneration of nerve cells, Parkure seeks to provide the medical industry with effective therapies to combat Parkinson's disease.

Transcriptogen Ltd. is focused on developing novel transcription factor inhibitors for cancer treatment. The company specializes in discovering inhibitors for key transcription factors such as NF-κB, STAT3, HIF1, and AP1, which are critical in regulating gene expression and cancer cell growth. Its lead compound, TSG1301, is a hybrid molecule that selectively binds to DNA, targeting the NF-κB recognition site and demonstrating effectiveness against breast and pancreatic cancer in preclinical models with low toxicity. Transcriptogen also offers a drug discovery platform, the TSG Drug Discovery Engine, to facilitate the identification of additional transcription factor inhibitors for future clinical applications. Furthermore, the company's pharmacogenomics assays are designed to identify patients with dysregulated transcription factor signaling, enabling tailored clinical trial participation and treatment strategies. Established in 2013 and based in Bath, United Kingdom, Transcriptogen aims to leverage the potential of small molecules in the fight against cancer.

PeptiGelDesign Ltd. specializes in the development and commercialization of self-assembling peptide-based hydrogels, which are designed to create defined three-dimensional microenvironments for various cell culture applications. The company offers products that are ready-to-use and easy to handle, suitable for culture dishes, multi-well plates, and cell culture inserts. These hydrogels serve as substrates for two-dimensional cell cultures and facilitate the encapsulation of cells for three-dimensional cultures. Additionally, PeptiGelDesign provides cardiovascular medical devices, including a biocompatible and biodegradable cardiac patch aimed at offering mechanical support to damaged heart tissue. Since its incorporation in 2013, the company has been based in Alderley Edge, United Kingdom, and also offers design services to further support the life science industry.

Filisia Interfaces Ltd. specializes in developing multimedia and multisensory devices aimed at enhancing training and rehabilitation for individuals with special education and rehabilitation needs. Founded in 2014 and based in London, the company offers Monoma, a training system designed for people with learning and physical disabilities. Filisia’s solutions leverage creative technology, integrating music and games to engage users in physical, cognitive, and communication skill development. The company's software features gamified rehabilitation exercises tailored to various conditions, with multiple difficulty levels to assess and improve user capabilities. Additionally, it provides valuable data analytics to track progress in physical and cognitive skills, addressing the challenges of traditional rehabilitation methods, which can be costly and monotonous. By focusing on innovative, engaging training solutions, Filisia aims to optimize therapy outcomes and reduce care costs for the estimated 150 million individuals worldwide with special education and rehabilitation needs.

Funnel Music is an innovative platform focused on the creation and marketing of new music. It aims to disrupt traditional methods by implementing a shared outcome agreement that facilitates the development of artists over extended periods with reduced financial burdens. The platform serves as an open community for artists and music professionals, allowing them to collaborate on new projects. By providing expert guidance and mentoring, Funnel Music enhances the career prospects of aspiring musicians, enabling them to navigate the complexities of the music industry more effectively.

Fen EP Limited is a developer of biomedical devices focused on preventing sudden cardiac death. The company specializes in invasive cardiac electrophysiology instrumentation, which is based on academic research involving paced electrogram fractionation analysis. This technology enables healthcare professionals to predict the risk of sudden cardiac death, allowing for timely interventions and potentially saving lives.

Pronec Ltd seeks to develop a new class of cancer therapy that causes tumours to simply die, using proprietary peptides. The Company has identified a lead candidate molecule that causes necrosis of a wide range of tumour cell lines in culture, but does not affect normal cell lines. Cancer cell necrosis refers to death of cancer cells within a tumour. This new class of compounds is protected by GB and international patent applications.

Elucid mHealth Limited is a medication technology company based in Manchester, United Kingdom, focused on enhancing clinical trial efficiencies through innovative adherence monitoring tools. Incorporated in 2013, the company developed Pill Connect, a sophisticated pill bottle that facilitates real-time remote monitoring of medication adherence. This product allows trial organizers to access vital data on patient dosing, including missed doses, new doses, and overall engagement metrics. By providing a feedback system that connects individual user doses to provider monitoring systems, Elucid mHealth aims to improve the accuracy and efficiency of clinical trials while addressing non-adherence issues.

Aurio Limited is focused on developing innovative solutions for individuals suffering from tinnitus, a common auditory condition characterized by the perception of sound without an external source. The company has created a unique musical application that utilizes masking technology to deliver tailored sound experiences, targeting the ear most affected by tinnitus. This approach not only helps alleviate the distressing symptoms associated with tinnitus, such as insomnia, anxiety, and poor concentration, but also enhances the quality of daily communication for users. With a significant portion of the adult population affected by this condition, particularly those over 60, Aurio's technology aims to provide relief and improve overall well-being for tinnitus sufferers through engaging and calming soundscapes.

Glyconics Ltd. is a diagnostics company based in Cambridge, United Kingdom, specializing in the development of portable infrared spectroscopy devices for the diagnosis and monitoring of chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Established in 2013, the company has created a hand-held device that utilizes Fourier transform infrared spectroscopy (FTIR) to analyze sputum samples for specific biomarkers associated with COPD. This innovative technology allows patients to perform diagnoses and monitor their health from home, facilitating early detection and management of respiratory diseases. By identifying particular spectral signatures in the samples, the device supports healthcare professionals in assessing and understanding patients' conditions more effectively.

Sky Medical Technology Limited develops innovative neuromuscular electro-stimulation medical devices aimed at enhancing vascular health. Their flagship products include the geko device, which stimulates the common peroneal nerve to activate muscle pumps and improve blood flow, and the firefly device, designed for athletes to enhance lower limb circulation for quicker recovery. The company's OnPulse™ therapy represents a significant advancement in bioelectronic medicine, offering clinically proven solutions for various acute and chronic circulatory conditions, including the prevention of blood clots, treatment of swelling post-surgery, and management of non-healing wounds. These devices are utilized by healthcare professionals, including surgeons, nurses, physiotherapists, and podiatrists, across NHS and private hospitals, as well as in clinical studies. Sky Medical Technology distributes its products globally, reaching markets in Asia, Europe, the Middle East, and North America. Founded in 2006 and based in High Wycombe, United Kingdom, the company addresses the needs of over forty million individuals facing vascular-related health challenges.

Videregen Limited is a regenerative medicine company based in Liverpool, United Kingdom, focused on developing organ replacement products to combat the chronic shortage of organs for transplantation. Established in 2011 as a spin-out from the Northwick Park Institute of Medical Research, the company specializes in creating biological scaffolds for organ regeneration, particularly targeting trachea, small bowel, and liver replacements. Utilizing decellularized organ scaffolds, Videregen's technology enables the seeding of these scaffolds with a patient’s own stem cells, resulting in personalized, non-immunogenic organ replacements. The company aims to pioneer commercially available organ replacement products, addressing critical health challenges and enhancing patient quality of life while potentially reducing healthcare costs.

AlgaeCytes Limited is a biotechnology company that specializes in the production of high-value omega oils and bioactive compounds derived from freshwater algae. Its innovative approach focuses on generating Omega 3 fatty acids, which are essential for various bodily functions, including blood clotting and brain cell membrane formation. Recognized for their numerous health benefits, Omega 3 fatty acids may contribute to heart health and have potential therapeutic effects on conditions such as cancer and autoimmune diseases. By utilizing algae, AlgaeCytes aims to reduce the reliance on dwindling fish stocks for omega-rich supplements, thereby catering to vegan consumers and promoting the availability of enhanced, organic health products in the healthcare, personal care, and nutraceutical markets.

Sky Medical Technology Limited develops innovative neuromuscular electro-stimulation medical devices aimed at enhancing vascular health. Their flagship products include the geko device, which stimulates the common peroneal nerve to activate muscle pumps and improve blood flow, and the firefly device, designed for athletes to enhance lower limb circulation for quicker recovery. The company's OnPulse™ therapy represents a significant advancement in bioelectronic medicine, offering clinically proven solutions for various acute and chronic circulatory conditions, including the prevention of blood clots, treatment of swelling post-surgery, and management of non-healing wounds. These devices are utilized by healthcare professionals, including surgeons, nurses, physiotherapists, and podiatrists, across NHS and private hospitals, as well as in clinical studies. Sky Medical Technology distributes its products globally, reaching markets in Asia, Europe, the Middle East, and North America. Founded in 2006 and based in High Wycombe, United Kingdom, the company addresses the needs of over forty million individuals facing vascular-related health challenges.

Connect Childcare develops nursery management software designed to enhance the efficiency of childcare facilities. Their integrated systems streamline administrative tasks such as assessments, progress reports, and planning, allowing staff to focus more on child development. By reducing paperwork and simplifying processes, Connect Childcare aims to improve the operational effectiveness of nurseries and ultimately contribute to better outcomes for children.

Arterius Limited is focused on developing an innovative bio-resorbable coronary scaffold, commonly referred to as a stent. This next-generation device is designed to dissolve over a period of 12 to 24 months, becoming absorbed by the body, which eliminates the need for surgical removal. By offering a solution that minimizes the frequency of surgeries or medical interventions, Arterius aims to enhance the postoperative quality of life for patients. The scaffold is engineered to match the delivery ease of traditional bare metal and drug-eluting stents while reducing acute platelet adherence and thrombus formation, providing a safer and more effective alternative in cardiovascular treatments.